Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
DISEASE
NETWORK
REGISTRY
PROJECTS
LOGIN
Experimental Rx
-
Nyheder
Projektet
Sponsor
Executive Committee
Writing Committee Strategic ...
Scientific and Bioethics Advis...
Becanovic
Busse
Frontali
Giorgini
Holmans
Mariotti
Norremolle
Reetz
Rickards
Saft
van Duijn
Valenza
Verellen
Public Documents
Central Coordination
Language Coordination
Fellowship Programme
Constitution
Article 1
Article 2
Article 3
Article 4
Article 5
Article 6
Article 7
Article 8
Article 9
Article 10
Article 11
Article 12
Documents
Voting/Nomination
Members
Deltagerlande
Austria
Belgium
Czech Republic
Denmark
Finland
France
Germany
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Russia
Spain
Coordination
Meeting 2008
Meeting 2009
Meeting 2010
Meeting 2011
Meeting 2012
Meeting 2013
HD Associations
Alicante
Badajoz
Barcelona - Bellvitge
Barcelona - Clinic i Provincia...
Barcelona - Mutua de Terra...
Barcelona - Santa Creu i Sa...
Barcelona - Merced
Bilbao
Burgos
Canaries
Granada
Fuenlabrada
Madrid-BTCIEN
Madrid - Clínico
Madrid - FJD
Madrid - RyC
Murcia
Oviedo
Palma de Mallorca
Pamplona
Santiago
Sevilla
Sevilla-HUVRocio
Sevilla-St-Ana
Valencia
Zaragoza
Sweden
Switzerland
U.K.
Coordination
HD Associations
Links
UKHDN
Standard of Care
Aberdeen
Ayr
Belfast
Birmingham
Blandford Forum
Bristol
Cambridge
Cardiff
Dundee
Edinburgh
Exeter
Fife
Forth Valley
Glasgow
Gloucester
Hull
Inverness
Launceston
Leeds
Leicester
Liverpool
London - Guy's Hospital
London - Hammersmith
London - NHNN
London - Royal Hospital
London - St. George´s
Manchester
Newcastle-Upon-Tyne
Northampton
Nottingham
Oxford
Plymouth
Poole
Preston
Reading
Sheffield
Southampton
Stoke-on-Trent
Swindon
Wrexham
Outside Europe
Arbejdsgrupper
Advanced HD
Dates
Meetings
Behavioural Phenotype
Dates
Meetings
Psycho appr. & interv. Sub...
Biological Modifiers
Biomarkers
Brain and Tissue Banking
Cognitive Phenotype
Environmental Modifiers
Functional Ability
Dates
Meetings
Genetic Testing
Genetic Modifiers
Health Economics
Imaging
Juvenile HD
Motor Phenotype
Neuroprotective Therapy
Physiotherapy
Dates
Meetings
Quality of Life
Dates
Meetings
Standard of Care
Dates
Meetings
Dieticians
SALT
Dental care
Occupational
Surgical Approaches
Symptomatic Research
Young Adults
Events
EHDN 2016
Announcement
Introduction
Registration
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Floor plan
Overduin Registration
CME points
Sponsoring
Travel Information
Hotel booking
Social activities
Reimbursement
Abstract Submission
Contacts
Documents
Feedback
EHDN 2014
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Pathogenic mechanisms
Animal models
Choreatic disorders - no...
Genetic modifiers
Wet Biomarkers
Imaging
Clin characteristics
Clin char-motor
Clin char-cognitive
Clin char - behaviour
Clin char-other
Clinical studies
Genetic testing
Clinical care
Experimental Rx
Clinical Rx
Non-scientific
Contacts
Feedback & Evaluation
EHDN 2010
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
EHDN 2004
Kommunikation
Job Offers
dato
description
size
author
document
04.08.26
In vivo efficacy of (CUG)n oligonucleotides to treat HD
32 kB
anonymous
p02-in-vivo-efficacy-oligonucleotides
04.08.26
Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease
32 kB
anonymous
p01-antisense-oligonucleotide-transcript
04.08.26
Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping
32 kB
anonymous
p03-exon-skipping
04.08.26
A Huntingtin peptide inhibits polyQ-hHtt associated defects
32 kB
anonymous
p04-polyq-hhtt-associated-defects
04.08.26
Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy
32 kB
anonymous
p07-glatiramer-acetate
04.08.26
Olesoxime improves specific features of the HD pathology
32 kB
anonymous
p06-olesoxime
04.08.26
Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!
32 kB
anonymous
p08-analysis-of-nrf2
Folder contains 7 documents.
about us
|
privacy statement
|
disclaimer
|
terms of use